China Pharma Holdings (CPHI) Depreciation & Amortization (CF) (2010 - 2026)
China Pharma Holdings (CPHI) posted Depreciation & Amortization (CF) of $980570.0 for Q1 2026, up 97.13% on a QoQ basis from $497425.0 in Q4 2025, and up 197.76% year-over-year from $329313.0 in Q1 2025.
China Pharma Holdings (CPHI) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
China Pharma Holdings' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $980570.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 197.76% year-over-year to $980570.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 2.65% YoY) and the FY2025 annual result came in at $1.5 million, down 42.57% from the prior year.
- Depreciation & Amortization (CF) was $980570.0 for Q1 2026 at China Pharma Holdings, up from $497425.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $980570.0 in Q1 2026 and bottomed at $320863.0 in Q2 2025.
- A 5-year average of $620968.1 and a median of $683094.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) sank 56.6% — and 2026, when it surged 197.76%.
- China Pharma Holdings' Depreciation & Amortization (CF) stood at $639425.0 in 2022, then climbed by 8.82% to $695835.0 in 2023, then tumbled by 35.61% to $448073.0 in 2024, then increased by 11.01% to $497425.0 in 2025, then soared by 97.13% to $980570.0 in 2026.
- Business Quant data shows CPHI's Depreciation & Amortization (CF) at $980570.0 in Q1 2026, $497425.0 in Q4 2025, and $356034.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 980,570.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 980,570.00 |
| Mar 31, 2026 | 980,570.00 |
| Dec 31, 2025 | 497,425.00 |
| Dec 31, 2025 | 497,425.00 |
| Sep 30, 2025 | 356,034.00 |
| Sep 30, 2025 | 356,034.00 |
| Jun 30, 2025 | 320,863.00 |
| Jun 30, 2025 | 320,863.00 |
| Mar 31, 2025 | 329,313.00 |
| Mar 31, 2025 | 329,313.00 |
| Dec 31, 2024 | 448,073.00 |
| Dec 31, 2024 | 448,073.00 |
| Sep 30, 2024 | 696,943.00 |
| Sep 30, 2024 | 696,943.00 |
| Jun 30, 2024 | 739,252.00 |
| Jun 30, 2024 | 739,252.00 |
| Mar 31, 2024 | 733,798.00 |
| Mar 31, 2024 | 733,798.00 |
| Dec 31, 2023 | 695,835.00 |
| Dec 31, 2023 | 695,835.00 |